AIM： To explore the relation between B-cell-specific Moloney murine leukemia virus insertion site 1 （Bmi-1） expression and the clinicopathological features of gastric carcinoma （GC）.METHODS： Immunohistochemistry...AIM： To explore the relation between B-cell-specific Moloney murine leukemia virus insertion site 1 （Bmi-1） expression and the clinicopathological features of gastric carcinoma （GC）.METHODS： Immunohistochemistry was used to detect the expression of Bmi-1 and ki-67. Doublelabeling staining was used to display the distribution of Bcl-2^＋/ki-67 cells in 162 cases of GC and its matched normal mucosa and precancerous lesion.RESULTS： The positive rate of Bmi-1 expression in GC（52.5%） was significantly higher than that in normal gastric mucosa （21.6%, X^2 = 33.088, P 〈 0.05）. The Bmi-1 expression in GC was closely related with the Lauren＇s and Borrmann＇s classification and clinicalstage （X^2 = 4.400, 6.122 and 11.190, respectively, P〈 0.05）. The expression of ki-67 was related to the Borrmann＇s classification （X^2 = 13.380, P 〈 0.05）.Bcl-2 expression was correlated with the Lauren＇s classification （Z2 = 4.725, P 〈 0.05）, and the Bmi-1 expression both in GC （rk = 0.157, P 〈 0.05） and inintestinal metaplasia （rk = 0.270, P 〈 0.05）.CONCLUSION： Abnormal Bmi-1 expression in GCmay be involved in cell proliferation, apoptosis andcancerization. This marker can objectively indicate theclinicopathological characteristics of GC.展开更多
目的:建立MCF-10AT乳腺癌癌前病变模型,探讨复方仙蓉颗粒(Compound Xian Rong Granules,CXRG)对MCF-10AT乳腺癌癌前病变模型的抑制作用。方法:采用体外接种MCF-10AT细胞于BALB/c雌性裸鼠,并肌注苯甲酸雌二醇建立乳腺癌癌前病变模型。随...目的:建立MCF-10AT乳腺癌癌前病变模型,探讨复方仙蓉颗粒(Compound Xian Rong Granules,CXRG)对MCF-10AT乳腺癌癌前病变模型的抑制作用。方法:采用体外接种MCF-10AT细胞于BALB/c雌性裸鼠,并肌注苯甲酸雌二醇建立乳腺癌癌前病变模型。随机分为模型组、CXRG组、三苯氧胺(Tamoxifen,TAM)组,每组20只。分接种后21、35、49、63天,分组观察裸鼠移植瘤重量及体积变化,观察移植瘤组织形态学变化。结果:接种后21天起裸鼠移植瘤组织均出现不同程度的增生。接种后35～49天,3组裸鼠移植瘤组织均出现不同程度的不典型增生,发生率为80%～100%。接种后63天,共出现3例浸润癌,其中模型组2/7,TAM组1/7;而CXRG组表现与49天时相似。结论:复方仙蓉颗粒能抑制或减缓MCF-10AT乳腺癌癌前病变的增殖,作用优于三苯氧胺。展开更多
目的:通过观察健脾活血方对胃癌前病变大鼠胃黏膜组织中CD44V6、MLH1及MSH2表达的影响,探讨健脾活血方对其干预的作用机制.方法:除正常组外,其他大鼠采用以N-甲基-N-硝基-N-亚硝基胍(N-methyl-N-nitro N-nitrosoguanidine,MNNG)为主同...目的:通过观察健脾活血方对胃癌前病变大鼠胃黏膜组织中CD44V6、MLH1及MSH2表达的影响,探讨健脾活血方对其干预的作用机制.方法:除正常组外,其他大鼠采用以N-甲基-N-硝基-N-亚硝基胍(N-methyl-N-nitro N-nitrosoguanidine,MNNG)为主同时配合0.3g/L雷尼替丁、400 mL/L乙醇及饥饱失常的多因素造模法建立胃癌前病变动物模型.将造模成功的40只大鼠随机分为模型组(0.9%氯化钠溶液)、胃复春组(0.86 g/kg)、健脾活血方高、中、低剂量组(32、16、8 g/kg),每组8只,每组每天给予等量(10 mL/kg)的不同药物灌胃一次,连续10 wk.实验末处死大鼠,给予相应处理后,快速免疫组织化学检测CD44V6、MLH1及MSH2表达情况.结果:模型组CD44V6表达与正常组相比明显升高(5.12±1.96 vs 0.25±0.46,P<0.01);健脾活血方高、中剂量组CD44V6表达与模型组相比均明显降低(2.25±0.71,3.25±0.31vs 5.12±1.96,P<0.01或P<0.05),低剂量组C D44V6表达与模型组比较差异无统计学意义(P>0.05);健脾活血方高剂量组CD44V6表达与胃复春组相比明显降低(2.25±0.71 vs4.62±1.19,P<0.01),中、低剂量组CD44V6表达与胃复春组比较差异无统计学意义(P>0.05).模型组MLH1、MSH2表达与正常组相比均明显降低(3.75±1.04 vs 8.00±0.926;3.62±1.69 vs 7.25±2.12,P<0.01);健脾活血方高、中、低剂量组MLH1、MSH2表达与模型组相比均明显升高(6.50±0.93,5.25±1.49,5.12±1.25 vs 3.75±1.04;6.62±2.13,6.00±1.51,5.50±1.41 vs 3.62±1.69,P<0.01或P<0.05);健脾活血方高剂量组MLH1表达与胃复春组相比明显升高(6.50±0.93 vs 4.88±1.25,P<0.05),中、低剂量组MLH1及高、中、低剂量组MSH2表达与胃复春组比较差异无统计学意义(P>0.05).结论:健脾活血方可通过降低CD44V6表达,上调MLH1、MSH2表达,减少细胞的非正常侵袭和转移,增强基因的错配修复功能,减少细胞的异常增殖和分化,发挥对大鼠胃癌前病变的治疗作用.展开更多
基金Supported by A special fund for Key University Laboratories from Department of Education of Liaoning Province, No. 2008S233
文摘AIM： To explore the relation between B-cell-specific Moloney murine leukemia virus insertion site 1 （Bmi-1） expression and the clinicopathological features of gastric carcinoma （GC）.METHODS： Immunohistochemistry was used to detect the expression of Bmi-1 and ki-67. Doublelabeling staining was used to display the distribution of Bcl-2^＋/ki-67 cells in 162 cases of GC and its matched normal mucosa and precancerous lesion.RESULTS： The positive rate of Bmi-1 expression in GC（52.5%） was significantly higher than that in normal gastric mucosa （21.6%, X^2 = 33.088, P 〈 0.05）. The Bmi-1 expression in GC was closely related with the Lauren＇s and Borrmann＇s classification and clinicalstage （X^2 = 4.400, 6.122 and 11.190, respectively, P〈 0.05）. The expression of ki-67 was related to the Borrmann＇s classification （X^2 = 13.380, P 〈 0.05）.Bcl-2 expression was correlated with the Lauren＇s classification （Z2 = 4.725, P 〈 0.05）, and the Bmi-1 expression both in GC （rk = 0.157, P 〈 0.05） and inintestinal metaplasia （rk = 0.270, P 〈 0.05）.CONCLUSION： Abnormal Bmi-1 expression in GCmay be involved in cell proliferation, apoptosis andcancerization. This marker can objectively indicate theclinicopathological characteristics of GC.
文摘目的:建立MCF-10AT乳腺癌癌前病变模型,探讨复方仙蓉颗粒(Compound Xian Rong Granules,CXRG)对MCF-10AT乳腺癌癌前病变模型的抑制作用。方法:采用体外接种MCF-10AT细胞于BALB/c雌性裸鼠,并肌注苯甲酸雌二醇建立乳腺癌癌前病变模型。随机分为模型组、CXRG组、三苯氧胺(Tamoxifen,TAM)组,每组20只。分接种后21、35、49、63天,分组观察裸鼠移植瘤重量及体积变化,观察移植瘤组织形态学变化。结果:接种后21天起裸鼠移植瘤组织均出现不同程度的增生。接种后35～49天,3组裸鼠移植瘤组织均出现不同程度的不典型增生,发生率为80%～100%。接种后63天,共出现3例浸润癌,其中模型组2/7,TAM组1/7;而CXRG组表现与49天时相似。结论:复方仙蓉颗粒能抑制或减缓MCF-10AT乳腺癌癌前病变的增殖,作用优于三苯氧胺。
文摘目的:通过观察健脾活血方对胃癌前病变大鼠胃黏膜组织中CD44V6、MLH1及MSH2表达的影响,探讨健脾活血方对其干预的作用机制.方法:除正常组外,其他大鼠采用以N-甲基-N-硝基-N-亚硝基胍(N-methyl-N-nitro N-nitrosoguanidine,MNNG)为主同时配合0.3g/L雷尼替丁、400 mL/L乙醇及饥饱失常的多因素造模法建立胃癌前病变动物模型.将造模成功的40只大鼠随机分为模型组(0.9%氯化钠溶液)、胃复春组(0.86 g/kg)、健脾活血方高、中、低剂量组(32、16、8 g/kg),每组8只,每组每天给予等量(10 mL/kg)的不同药物灌胃一次,连续10 wk.实验末处死大鼠,给予相应处理后,快速免疫组织化学检测CD44V6、MLH1及MSH2表达情况.结果:模型组CD44V6表达与正常组相比明显升高(5.12±1.96 vs 0.25±0.46,P<0.01);健脾活血方高、中剂量组CD44V6表达与模型组相比均明显降低(2.25±0.71,3.25±0.31vs 5.12±1.96,P<0.01或P<0.05),低剂量组C D44V6表达与模型组比较差异无统计学意义(P>0.05);健脾活血方高剂量组CD44V6表达与胃复春组相比明显降低(2.25±0.71 vs4.62±1.19,P<0.01),中、低剂量组CD44V6表达与胃复春组比较差异无统计学意义(P>0.05).模型组MLH1、MSH2表达与正常组相比均明显降低(3.75±1.04 vs 8.00±0.926;3.62±1.69 vs 7.25±2.12,P<0.01);健脾活血方高、中、低剂量组MLH1、MSH2表达与模型组相比均明显升高(6.50±0.93,5.25±1.49,5.12±1.25 vs 3.75±1.04;6.62±2.13,6.00±1.51,5.50±1.41 vs 3.62±1.69,P<0.01或P<0.05);健脾活血方高剂量组MLH1表达与胃复春组相比明显升高(6.50±0.93 vs 4.88±1.25,P<0.05),中、低剂量组MLH1及高、中、低剂量组MSH2表达与胃复春组比较差异无统计学意义(P>0.05).结论:健脾活血方可通过降低CD44V6表达,上调MLH1、MSH2表达,减少细胞的非正常侵袭和转移,增强基因的错配修复功能,减少细胞的异常增殖和分化,发挥对大鼠胃癌前病变的治疗作用.
